Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GSK with free AI briefings, catalyst countdowns, and dilution alerts.

GSK · GSK plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$3B Cash on Hand
CF+ Cash Runway
0.8% Short Interest
$59.12 Analyst Target (9)
Follow GSK by email Get an email when GSK reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GSK, unsubscribe in one click. Privacy

📣 What GSK Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Belimumab
FDA approved Jul 2017 · Benlysta
Systemic Lupus Erythematosus Phase 4 · NCT01632241 Completed
Momelotinib
FDA approved Sep 2023 · Ojjaara
Primary Myelofibrosis Phase 3 · NCT04173494 Completed
Dostarlimab (TSR-042)
FDA approved Apr 2021 · Jemperli
Ovarian Clear Cell Carcinoma Phase 1/2 · NCT06065462 Recruiting
Standard therapy Systemic Lupus Erythematosus Phase 4 · NCT01632241 Completed
Camlipixant Cough Phase 3 · NCT05600777 Active not recruiting
Nab-paclitaxel Metastatic Pancreatic Ductal Adenocarcinoma Phase 3 · NCT02101021 Terminated
Protein Phosphatase 2A Inhibitor LB-100 Ovarian Clear Cell Carcinoma Phase 1/2 · NCT06065462 Recruiting
RPT193 Asthma Phase 2 · NCT05935332 Terminated
HS235 Pulmonary Hypertension Phase 1/2 · NCT07123779 Recruiting
Ozureprubart Immune System Diseases Phase 2 · NCT07220811 Active not recruiting
DNA Interference Oligonucleotide PNT2258 Lymphoma, Diffuse Large B-Cell Phase 2 · NCT02226965 Completed
Tivumecirnon (FLX475) Advanced Melanoma Phase 2 · NCT04894994 Terminated
Chk1 Inhibitor SRA737 Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL) Phase 1/2 · NCT02797964 Completed
HS135 Heart Failure With Preserved Ejection Fraction Phase 1 · NCT06581159 Terminated
Rabeprazole Cough Phase 1 · NCT05899829 Completed
Velzatinib (IDRX-42) Gastrointestinal Neoplasms Phase 1 · NCT05489237 Active not recruiting

Also used in these trials (approved or third-party drugs, not GSK's own candidates): Ruxolitinib, Gemcitabine Hydrochloride, Danazol, Alitretinoin, Ipilimumab, Pembrolizumab, Bortezomib, Trametinib, Rifampin, Gemfibrozil, Dabigatran Etexilate.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GSK holds $3B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GSK files for a raise →

👥 Who Owns GSK

Insiders 0.4% Institutions (1187 holders) 17.2% Public and other holders 82.4%
HolderTypeShares% of sharesAs of
FMR LLC Institution (13G, 5%+) 234,936,061 5.44% 2026-03-31
Dodge & Cox Inc. Institution (13F) 43,183,117 1.00% 2026-09-30
Fisher Asset Management, LLC Institution (13F) 35,351,693 0.82% 2026-09-30
Primecap Management Company Institution (13F) 25,192,138 0.58% 2026-09-30
GSK plc
10% owner
Insider 18,245,691 0.42% 2025-12-11
Wellington Management Group, LLP Institution (13F) 9,650,852 0.22% 2026-09-30
JTC Employer Solutions Trustee Ltd. Institution (13F) 8,077,477 0.19% 2026-09-30
Morgan Stanley Institution (13F) 7,584,742 0.18% 2026-09-30
Price (T.Rowe) Associates Inc Institution (13F) 6,712,097 0.16% 2026-09-30
Goldman Sachs Group Inc Institution (13F) 6,021,779 0.14% 2026-09-30

Share count 4,315,445,026 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.

📅 Past FDA Decisions & Stock Reactions

DateDrugTypeRun-up 30dDecision 1dAfter 5d
2026-10-19 Jemperli sBLA -3% -0.1% +2.5%

Browse all historical PDUFA outcomes →

Get the full GSK picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GSK and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.